Shocked by the surfacing of fake Chinese medicines with 'Made in India' logo in Africa, the government has asked its missions in the region to step up vigil for protecting the nation's image and market.
"Commerce and External Affairs ministries have written to our Mission in Africa that such type of things should be monitored strictly," a senior Commerce Department official told PTI.
Recently, there were seizure of fake drugs in Nigeria which were carrying 'Made in India' label but were allegedly manufactured in China. India has taken the issue very seriously as this could damage the reputation of the Indian pharmaceutical industry in the global market.
India has also raised the issue with China. Though China has assured of investigations in the matter, Indian authorities have not been given any time frame, the official said.
"We do not know how fast China will conduct the enquiry and what action they will take against those responsible," he added.
Sources, however, said it was difficult to keep tab on counterfeit drugs in Africa as most of the medicines find way to the interior regions.
Besides, most of the African countries do not have a well-knitted mechanism to check spurious imports.
"Such incidents can damage our markets," the official said. India's exports around seven billion dollars worth of generic pharmaceutical products and Africa accounts for a sizable portion of this.
Indian drug companies such as Cipla, Dr Reddy's and Aurbindo Pharma have increased their shipments to the region and are posing a challenge to the multinational firms for which Africa is considered as a traditional market.
According to industry estimates, global sales of counterfeit drugs are expected to reach 75 billion dollars by 2010, a more than 90 per cent increase from 2005.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
